Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility study of metastatic lesion sequencing to predict irinotecan response
NL-OMON39548Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of irinotecan in colorectal cancer (CRC) and Nonhematologic neoplasms, sponsored by University Medical Center Utrecht. Primary endpoint: Correlation of early volumetric response with mutational profile. Started Nov 2011; status: active, not recruiting.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON39548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39548.